Welcome to our dedicated page for Intellia Therapeutics SEC filings (Ticker: NTLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Intellia Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Intellia Therapeutics's regulatory disclosures and financial reporting.
Intellia Therapeutics, Inc. (NTLA) Form 4: Director Georgia Keresty reported new equity compensation dated 06/11/2025.
- 8,000 restricted stock units (RSUs) granted at $0 cost; each RSU converts into one common share.
- 11,450 stock options with a $8.37 exercise price; the option vests in full on the earlier of the first anniversary of grant or the next annual shareholder meeting and expires 06/10/2035.
- After the grant, Keresty directly owns 31,883 common shares.
No shares were sold or disposed of, and the filing reflects routine non-employee director compensation with negligible dilution and no impact on control or earnings.